Recursion Pharmaceuticals, Inc. RXRX Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s total liabilities?
- Recursion Pharmaceuticals, Inc. (RXRX) reported total liabilities of $314.75M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s total liabilities changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s total liabilities decreased by 15.2% year-over-year, from $371.29M to $314.75M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s total liabilities?
- Over 5 years (2020 to 2025), Recursion Pharmaceuticals, Inc.'s total liabilities has grown at a 43.4% compound annual growth rate (CAGR), from $56.56M to $343.27M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.